[go: up one dir, main page]

DK216189D0 - Rekombinant antistof - Google Patents

Rekombinant antistof

Info

Publication number
DK216189D0
DK216189D0 DK216189A DK216189A DK216189D0 DK 216189 D0 DK216189 D0 DK 216189D0 DK 216189 A DK216189 A DK 216189A DK 216189 A DK216189 A DK 216189A DK 216189 D0 DK216189 D0 DK 216189D0
Authority
DK
Denmark
Prior art keywords
pct
sec
recombinant antibody
date
surface pocket
Prior art date
Application number
DK216189A
Other languages
English (en)
Other versions
DK172630B1 (da
DK216189A (da
Inventor
Mark William Bodmer
John Robert Adair
Nigel Richard Whittle
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Ltd filed Critical Celltech Ltd
Publication of DK216189D0 publication Critical patent/DK216189D0/da
Publication of DK216189A publication Critical patent/DK216189A/da
Application granted granted Critical
Publication of DK172630B1 publication Critical patent/DK172630B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK198902161A 1987-09-04 1989-05-03 Modificeret antistofmolekyle eller derivat heraf og fremgangsmåde til fremstilling af det modificerede antistofmolekyle DK172630B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878720833A GB8720833D0 (en) 1987-09-04 1987-09-04 Recombinant dna product
GB8720833 1987-09-04
PCT/GB1988/000730 WO1989001974A1 (en) 1987-09-04 1988-09-05 Recombinant antibody
GB8800730 1988-09-05

Publications (3)

Publication Number Publication Date
DK216189D0 true DK216189D0 (da) 1989-05-03
DK216189A DK216189A (da) 1989-05-03
DK172630B1 DK172630B1 (da) 1999-03-22

Family

ID=10623277

Family Applications (3)

Application Number Title Priority Date Filing Date
DK198902161A DK172630B1 (da) 1987-09-04 1989-05-03 Modificeret antistofmolekyle eller derivat heraf og fremgangsmåde til fremstilling af det modificerede antistofmolekyle
DK216089A DK216089D0 (da) 1987-09-04 1989-05-03 Rekombinant antistof og fremgangsmaade til dets fremstilling
DK215889A DK215889A (da) 1987-09-04 1989-05-03 Rekombinant antistof

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK216089A DK216089D0 (da) 1987-09-04 1989-05-03 Rekombinant antistof og fremgangsmaade til dets fremstilling
DK215889A DK215889A (da) 1987-09-04 1989-05-03 Rekombinant antistof

Country Status (11)

Country Link
US (1) US5219996A (da)
EP (3) EP0348442B1 (da)
JP (3) JPH02501191A (da)
AT (2) ATE102254T1 (da)
AU (3) AU611202B2 (da)
CA (2) CA1337640C (da)
DE (2) DE3877955T2 (da)
DK (3) DK172630B1 (da)
FI (3) FI892135L (da)
GB (1) GB8720833D0 (da)
WO (3) WO1989001782A1 (da)

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU625856B2 (en) * 1987-07-15 1992-07-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
WO1989007142A1 (en) * 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
BR8907126A (pt) * 1988-10-19 1991-02-13 Dow Chemical Co Uma nova familia de anticorpos modificados,de elevada afinidade,para tratamento de cancer
US5215889A (en) * 1988-11-18 1993-06-01 The Regents Of The University Of California Catalytic and reactive polypeptides and methods for their preparation and use
US5162218A (en) * 1988-11-18 1992-11-10 The Regents Of The University Of California Conjugated polypeptides and methods for their preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5354554A (en) * 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
US5714149A (en) * 1989-02-10 1998-02-03 Celltech Therapeutics Limited Crosslinked antibodies and processes for their preparation
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
GB8903021D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8916400D0 (en) * 1989-07-18 1989-09-06 Dynal As Modified igg3
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US5185433A (en) * 1990-04-09 1993-02-09 Centocor, Inc. Cross-linking protein compositions having two or more identical binding sites
US6495137B1 (en) 1990-04-19 2002-12-17 The Dow Chemical Company Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains
US5976531A (en) * 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
AU654563B2 (en) * 1991-07-24 1994-11-10 Imperial Chemical Industries Plc Proteins
WO1993006217A1 (en) * 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
WO1993012231A1 (en) * 1991-12-13 1993-06-24 Dow Chemical (Australia) Limited Composite antibodies of human subgroup iv light chain capable of binding to tag-72
EP0571613B1 (en) * 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
IL104620A (en) 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
GB9422383D0 (en) * 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US20050033033A1 (en) * 1998-05-04 2005-02-10 Heinz Kohler Trans-membrane-antibody induced inhibition of apoptosis
US7569674B2 (en) * 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
US20040185039A1 (en) * 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US6365124B1 (en) * 1998-02-06 2002-04-02 Biocrystal, Ltd. Compositions for detecting and surgically removing lymphoid tissue involved in tumor progression
US20090208418A1 (en) * 2005-04-29 2009-08-20 Innexus Biotechnology Internaltional Ltd. Superantibody synthesis and use in detection, prevention and treatment of disease
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
JP4992068B2 (ja) * 2000-01-27 2012-08-08 メディミューン，エルエルシー 超高親和性中和抗体
JP3439195B2 (ja) 2000-02-17 2003-08-25 浜松ホトニクス株式会社 抗原の定量的検出方法
AU4002001A (en) * 2000-03-01 2001-09-12 Med Immune Inc High potency recombinant antibodies and method for producing them
ATE353913T1 (de) 2000-04-21 2007-03-15 Fuso Pharmaceutical Ind Neue collectine
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ES2316919T3 (es) 2000-12-05 2009-04-16 Alexion Pharmaceuticals, Inc. Anticuerpos diseñados racionalmente.
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
WO2002062850A2 (en) * 2001-02-02 2002-08-15 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
EP1366067B1 (en) * 2001-03-07 2012-09-26 Merck Patent GmbH Expression technology for proteins containing a hybrid isotype antibody moiety
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2490659C (en) 2002-06-28 2014-08-19 Syed V. S. Kashmiri Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
CA2499300A1 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
KR101412271B1 (ko) 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
EP1641827A2 (en) * 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
PL1644412T5 (pl) 2003-07-01 2019-01-31 Ucb Biopharma Sprl Modyfikowane fragmenty Fab przeciwciała
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
EP1651663B1 (en) * 2003-08-08 2017-05-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
WO2005051422A1 (en) * 2003-11-21 2005-06-09 Celltech R & D Limited Method for the treatment of multiple sclerosis by inhibiting il-17 activity
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
WO2005103086A1 (en) 2004-04-23 2005-11-03 Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
US7521541B2 (en) * 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006050166A2 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
BRPI0607486B8 (pt) 2005-03-03 2021-05-25 Immunomedics Inc anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
US20100104564A1 (en) * 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
PT1912675E (pt) 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
US8129505B2 (en) * 2005-09-14 2012-03-06 Ucb Pharma S.A. Comb polymers
ES2525325T3 (es) 2005-12-09 2014-12-22 Ucb Pharma S.A. Moléculas de anticuerpo que tienen especificidad por la IL-6 humana
JP5259423B2 (ja) 2006-02-01 2013-08-07 セファロン・オーストラリア・ピーティーワイ・リミテッド ドメイン抗体構築物
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
BR122020022640B1 (pt) 2007-03-22 2022-03-29 UCB Biopharma SRL Molécula de dna codificando proteínas de ligação a cd154, vetor, célula hospedeira e método de produção das referidas proteínas
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
JP2010528664A (ja) * 2007-06-08 2010-08-26 ダウ グローバル テクノロジーズ インコーポレイティド Ｃｈ１ドメインの切断による可溶性抗体断片の発現
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
JP5615181B2 (ja) 2007-11-27 2014-10-29 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 関節炎の予防及び治療のための組成物及び方法
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
JP2011509675A (ja) * 2008-01-18 2011-03-31 メディミューン，エルエルシー 部位特異的コンジュゲーションのためのシステイン操作抗体
WO2009120903A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
SG10201505038TA (en) 2009-02-17 2015-07-30 Ucb Biopharma Sprl Antibody molecules having specificity for human ox40
GB0904214D0 (en) * 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
JP5795759B2 (ja) 2009-04-16 2015-10-14 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ＴＮＦ−α抗体およびその用途
MX2011013781A (es) 2009-06-17 2012-05-29 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos.
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
GB0916630D0 (en) 2009-09-22 2009-11-04 Secr Defence Antibody
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP3421493B1 (en) 2009-10-16 2024-01-17 Progastrine et Cancers S.à r.l. Monoclonal antibodies to progastrin and their uses
JP6095368B2 (ja) 2009-10-27 2017-03-15 ユセベ ファルマ ソシエテ アノニム 機能改変するＮａｖ１．７抗体
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
CA2777825A1 (en) 2009-10-28 2011-05-19 Abbott Biotherapeutics Corp. Anti-egfr antibodies and their uses
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
EP2513148B1 (en) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
ES2550060T3 (es) 2010-03-12 2015-11-04 Abbvie Biotherapeutics Inc. Proteínas de CTLA4 y sus usos
TR201903279T4 (tr) 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP2579897A1 (en) 2010-06-08 2013-04-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
PL2663577T3 (pl) 2011-01-14 2017-09-29 Ucb Biopharma Sprl Przeciwciało wiążące IL-17A i IL-17F
HK1199463A1 (en) 2011-09-16 2015-07-03 Ucb医药有限公司 Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2783214A2 (en) 2011-11-23 2014-10-01 The Board of Regents of The University of Texas System Proteomic identification of antibodies
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
ES2874493T3 (es) * 2013-02-08 2021-11-05 Novartis Ag Sitios específicos para modificar anticuerpos para generar inmunoconjugados
EP2970436B1 (en) 2013-03-15 2018-09-05 AbbVie Biotherapeutics Inc. Fc variants
RU2015144033A (ru) 2013-03-15 2017-04-26 Эббви Байотекнолоджи Лтд. Антитела против cd25 и их применения
EP3216804A3 (en) 2013-03-15 2017-12-20 AbbVie Biotechnology Ltd. Anti-cd25 antibodies and their uses
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
SG11201605862WA (en) 2014-01-20 2016-08-30 Eveon Process for reconstitution of a solid form of a pharmaceutical composition
WO2015123265A1 (en) 2014-02-11 2015-08-20 Seattle Genetics, Inc. Selective reduction of proteins
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP2944962A1 (en) 2014-05-14 2015-11-18 UCB Biopharma SPRL Method for determining antibody specificity
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
US10035823B2 (en) 2014-09-29 2018-07-31 The Regents Of The University Of California Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions
PT3221346T (pt) 2014-11-21 2020-10-23 Bristol Myers Squibb Co Anticorpos compreendendo regiões constantes de cadeia pesada modificadas
WO2016081748A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
SI3237432T1 (sl) 2014-12-22 2023-12-29 UCB Biopharma SRL Izdelava proteinov
CN107406493B (zh) 2015-03-06 2021-08-13 康诺贝林伦瑙有限公司 具有改善的半衰期的经修饰的血管性血友病因子
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
KR20170138570A (ko) 2015-04-30 2017-12-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
MX2017014782A (es) 2015-05-27 2018-02-15 Ucb Biopharma Sprl Metodo para el tratamiento de enfermedad neurologica.
MX2017015817A (es) 2015-07-06 2018-04-10 Ucb Biopharma Sprl Anticuerpos de union a tau.
MX2018001566A (es) * 2015-08-07 2019-04-25 Imaginab Inc Construcciones de union a antigeno para moleculas diana.
EP3360960A4 (en) 2015-08-19 2019-03-20 Riken ANTIBODIES WITH INGREDIENTS OF NON-NATURAL AMINO ACID
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
MY196489A (en) 2015-10-27 2023-04-17 UCB Biopharma SRL Methods of Treatment Using Anti-IL-17A/F Antibodies
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
GB201602414D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Biological materials and uses thereof
KR102392746B1 (ko) 2016-03-17 2022-04-29 누맙 이노베이션 아게 항-TNFα-항체 및 이의 기능성 단편
DK3219726T3 (da) 2016-03-17 2020-12-07 Tillotts Pharma Ag Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
CN109153718B (zh) 2016-03-17 2022-02-08 努玛治疗有限公司 抗TNFα抗体及其功能片段
CA3011502A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnf.alpha.-antibodies and functional fragments thereof
DK3219727T3 (da) 2016-03-17 2021-01-04 Tillotts Pharma Ag Anti-THF-alpha-antistoffer og funktionelle fragmenter deraf
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
EP3504244A4 (en) 2016-08-26 2020-08-19 Agency for Science, Technology and Research MACROPHAGE-STIMULATING PROTEIN RECEPTOR ANTIBODIES (OR OF NANTAIS ORIGINAL RON-RECEPTOR) AND THEIR USES
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
AU2018227807B2 (en) 2017-02-28 2024-10-10 Seagen Inc. Cysteine mutated antibodies for conjugation
WO2019004943A1 (en) 2017-06-30 2019-01-03 Aslan Pharmaceuticals Pte Ltd METHOD OF TREATMENT USING ANTIBODY DIRECTED AGAINST IL-13R
DK3720879T3 (da) 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
WO2019166499A1 (en) 2018-02-27 2019-09-06 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
PT3806898T (pt) 2018-06-18 2025-12-02 UCB Biopharma SRL Antagonista de gremlin-1 para utilização no tratamento do cancro
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
AR117653A1 (es) 2018-10-16 2021-08-25 UCB Biopharma SRL Método para tratamiento de miastenia grave
AU2020247175A1 (en) 2019-03-26 2021-10-14 Aslan Pharmaceuticals Pte Ltd Treatment employing anti-IL-13R antibody or binding fragment thereof
BR112022003635A2 (pt) 2019-09-04 2022-05-24 Pf Medicament Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
WO2021091899A1 (en) 2019-11-04 2021-05-14 Genisphere, Llc Brain-specific angiogenesis inhibitor 1 (bai1) antibodies and uses thereof
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
BR112023008265A2 (pt) 2020-12-07 2024-02-06 UCB Biopharma SRL Anticorpos contra interleucina-22
AR125581A1 (es) 2020-12-07 2023-08-02 UCB Biopharma SRL Anticuerpos multiespecíficos y combinaciones de anticuerpos
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
US20240158503A1 (en) 2021-03-03 2024-05-16 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof
CN117545778A (zh) 2021-04-30 2024-02-09 皮埃尔法布雷医药公司 新的稳定抗vista抗体
US20240254224A1 (en) 2021-05-03 2024-08-01 UCB Biopharma SRL Antibodies
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023075702A1 (en) 2021-10-29 2023-05-04 Aslan Pharmaceuticals Pte Ltd Anti-il-13r antibody formulation
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
WO2023163659A1 (en) 2022-02-23 2023-08-31 Aslan Pharmaceuticals Pte Ltd Glycosylated form of anti-il13r antibody
JP2025529908A (ja) 2022-08-26 2025-09-09 アスラン ファーマシューティカルズ ピーティーイー リミテッド 高濃度抗ｉｌ１３ｒ抗体製剤
EP4594352A1 (en) 2022-09-06 2025-08-06 ASLAN Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant
CN120530134A (zh) 2022-12-22 2025-08-22 朱利叶斯-马克西米利维尔茨堡大学 用作凝血剂的抗体
EP4431526A1 (en) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi antibodies and functional fragments thereof
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS63501765A (ja) * 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product

Also Published As

Publication number Publication date
DK215889D0 (da) 1989-05-03
WO1989001974A1 (en) 1989-03-09
CA1337640C (en) 1995-11-28
WO1989001783A2 (en) 1989-03-09
FI892135A0 (fi) 1989-05-03
ATE102254T1 (de) 1994-03-15
EP0348442A1 (en) 1990-01-03
DE3877955D1 (de) 1993-03-11
FI892136A0 (fi) 1989-05-03
FI892135A7 (fi) 1989-05-03
FI892136L (fi) 1989-05-03
WO1989001783A3 (en) 1989-04-20
JPH02501800A (ja) 1990-06-21
EP0347433A1 (en) 1989-12-27
FI892137A0 (fi) 1989-05-03
JP2761012B2 (ja) 1998-06-04
JP2675380B2 (ja) 1997-11-12
DE3888172T2 (de) 1994-06-30
EP0348442B1 (en) 1993-01-27
FI892135L (fi) 1989-05-03
JPH02501191A (ja) 1990-04-26
CA1337641C (en) 1995-11-28
AU2421888A (en) 1989-03-31
AU2301388A (en) 1989-03-31
US5219996A (en) 1993-06-15
DE3877955T2 (de) 1993-07-22
DK215889A (da) 1989-05-03
DK172630B1 (da) 1999-03-22
FI892136A7 (fi) 1989-05-03
DE3888172D1 (de) 1994-04-07
EP0329755A1 (en) 1989-08-30
DK216089A (da) 1989-05-03
GB8720833D0 (en) 1987-10-14
FI892137L (fi) 1989-05-03
AU617367B2 (en) 1991-11-28
DK216089D0 (da) 1989-05-03
FI892137A7 (fi) 1989-05-03
ATE84973T1 (de) 1993-02-15
EP0347433B1 (en) 1994-03-02
AU614303B2 (en) 1991-08-29
WO1989001782A1 (en) 1989-03-09
AU611202B2 (en) 1991-06-06
JPH02501190A (ja) 1990-04-26
DK216189A (da) 1989-05-03
AU2301688A (en) 1989-03-31

Similar Documents

Publication Publication Date Title
DE3877955D1 (de) Veraenderter antikoerper.
ES2068907T3 (es) Secuencias de nucleotidos que codifican una proteina con actividad ureasica.
BR8806158A (pt) Processo para remocao de oxidos de enxofre de um gas,processo de conversao de hidrocarbonetos que emprega um material de alimentacao de hidrocarbonetos contendo enxofre;composicao de materia;e processo para producao de um componente metalico contendo oxigenio
FR2437213A1 (fr) Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
SE8204810D0 (sv) Recombinant dna molecule, transformed microorganism and process for producing protein a
HU903425D0 (en) Process for the production of medicines closely related to the calcytonine gene for treating potential disorder
ES2058538T3 (es) Compuestos de proteina a purificados y procedimiento para su preparacion.
PT92148A (pt) Processo para a preparacao de pomada contendo colesterol para o tratamento topico de dermatoses
DE69006395D1 (de) Nährstoff-Zusammensetzungen für die Ergänzung an Aminosäuren bei Säugetieren.
NO895028D0 (no) Ny chimerisk transformerende vekstfaktor-beta.
PT81528B (pt) Processo para a sintese de peptideos
ATE108709T1 (de) Verfahren zum herstellen von klinkern.
PT91132A (pt) Processo para a preparacao de hidrohaletos de rifapentina
GB8414354D0 (en) Purifying protein
DE59903230D1 (de) Vorrichtung zum Vereinzeln und zur Weitergabe von Stabmaterial, insbesondere von Rohren und Stangen
DK0383599T3 (da) Protein-anticancermiddel
ATE113986T1 (de) Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
ES2173879T3 (es) Procedimiento para la preparacion de conjugados a base de un participe especifico en la fijacion y de una proteina que contiene hidratos de carbono
DK549886D0 (da) Enzymproces
ES2065525T3 (es) Mejoras relacionadas con el radiomarcado de las proteinas.
AU1062588A (en) Immunoassay utilizing microparticle neutralization
ES2049021T3 (es) Metodo de recuperar la proteina epi purificada a partir de una solucion, especialmente una solucion de fermentacion.
HU9302658D0 (en) Process for completing traditional pair compasses of 2 mm graphite point to that with element suitable for holding thin (0.8, 0.5, 0.3 mm) graphite point
ES262943U (es) Util escritor, ambivalente.
BR8006731A (pt) Processo de metalizacao interna aplicado em ampola para garrafa termica

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired